title: Can we discontinue disease-modifying treatments in multiple sclerosis patients? Yes.
authors.affiliation: Université de Nantes, 1, rue Gaston-Veil, BP 53508, 44035 Nantes cedex 1, France. Electronic address: david.laplaud@chu-nantes.fr.
authors.forename: David
authors.initials: D
authors.lastname: Laplaud
mesh_terms: D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D000069442:Natalizumab / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D011256:Pregnancy Outcome; D012008:Recurrence; D012307:Risk Factors; D028761:Withholding Treatment
chemical_list: D007166:Immunosuppressive Agents; D000069442:Natalizumab
keywords: Multiple sclerosis; Pregnancy; Risk; Therapeutic failure; Treatment